[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=9cfad946c26b1028d6636a32d61ffe22b753930d698d2c9343e09c10af29ad91",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732206900,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 131599136,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=9cfad946c26b1028d6636a32d61ffe22b753930d698d2c9343e09c10af29ad91"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy",
    "summary": "The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past year...",
    "url": "https://finnhub.io/api/news?id=bc0eb985720c9d9e802e5a3198332240533eaf4602598ac1aa7c5b9430d45d1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732186815,
      "headline": "AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy",
      "id": 131542609,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/b1235bf6d18ebc2cd7323427468d0693",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past year...",
      "url": "https://finnhub.io/api/news?id=bc0eb985720c9d9e802e5a3198332240533eaf4602598ac1aa7c5b9430d45d1f"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake Immunotherapeutics: A Somewhat Complicated Story",
    "summary": "MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected. Read the full report.",
    "url": "https://finnhub.io/api/news?id=d8804c45dc0a76ad93ca257c6d6973b3343e0a320c6d0316648e6632731f2179",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732184709,
      "headline": "MoonLake Immunotherapeutics: A Somewhat Complicated Story",
      "id": 131539801,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295493003/image_1295493003.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected. Read the full report.",
      "url": "https://finnhub.io/api/news?id=d8804c45dc0a76ad93ca257c6d6973b3343e0a320c6d0316648e6632731f2179"
    }
  }
]